Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Circulating Epigenetic Biomarkers In Malignant Pleural Mesothelioma: State Of The Art And Critical Evaluation

L. Ferrari, M. Carugno, C. Mensi, A. Pesatori
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer, which originates from the mesothelial cells of the pleura and is associated with asbestos exposure. In light of its aggressive nature, late diagnosis and dismal prognosis, there is an urgent need for identification of biomarkers in easily accessible samples (such as blood) for early diagnosis of MPM. In the last 10 years, epigenetic markers, such as DNA methylation and microRNAs (miRNAs), have gained popularity as possible early diagnostic and prognostic biomarkers in cancer research. The aim of this review is to provide a critical analysis of the current evidences on circulating epigenetic biomarkers for MPM and on their translational potential to the clinical practice for early diagnosis and for prognosis.
This paper references
10.1016/S1470-2045(09)70134-2
A review of human carcinogens--Part C: metals, arsenic, dusts, and fibres.
K. Straif (2009)
10.1371/journal.pone.0057841
Dampening Enthusiasm for Circulating MicroRNA in Breast Cancer
R. Leidner (2013)
10.1038/nrg.2015.10
Unique features of long non-coding RNA biogenesis and function
Jeffrey J. Quinn (2015)
10.1096/fj.15-271312
Normalization panels for the reliable quantification of circulating microRNAs by RT‐qPCR
M. Kok (2015)
10.3390/ht7030020
Genomics and Epigenetics of Malignant Mesothelioma
Adam P Sage (2018)
10.2217/epi.11.22
Epigenetics and lifestyle.
J. Alegría-Torres (2011)
10.1007/s10552-009-9357-4
Ionizing radiation: a risk factor for mesothelioma
J. Goodman (2009)
10.1038/ng.3520
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
R. Bueno (2016)
10.21037/atm.2017.04.29
Mesothelioma: recent highlights.
M. Carbone (2017)
10.1016/S0140-6736(04)17102-X
Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids
F. Lopez-Rios (2004)
10.21037/atm.2017.04.06
The Cappadocia mesothelioma epidemic: its influence in Turkey and abroad.
S. Emri (2017)
Epigenetics and lifestyle. Epigenomics
JA Alegria-Torres (2011)
10.3978/j.issn.2225-319X.2012.10.05
Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future.
A. Nowak (2012)
10.1016/j.jtho.2015.10.003
Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma
A. Billè (2016)
10.2217/bmm-2017-0224
Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients.
M. Matboli (2018)
10.1373/clinchem.2015.239459
Data Normalization Strategies for MicroRNA Quantification.
H. Schwarzenbach (2015)
10.3389/fgene.2013.00119
Circulating miRNAs: cell–cell communication function?
A. Turchinovich (2013)
10.3390/ijerph15051000
Global Asbestos Disaster
S. Furuya (2018)
10.1289/ehp.10195
Cancer Mortality and Incidence of Mesothelioma in a Cohort of Wives of Asbestos Workers in Casale Monferrato, Italy
D. Ferrante (2007)
10.1073/PNAS.0307323101
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.
G. Calin (2004)
10.1371/journal.pone.0176680
Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease
T. Cavalleri (2017)
10.1586/ers.11.51
Simian virus 40 transformation, malignant mesothelioma and brain tumors
Fang Wei Qi (2011)
10.1016/j.jtho.2018.10.163
Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos‐Exposed Subjects
S. Guarrera (2019)
10.18632/oncotarget.14712
Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis
Dongxu Pei (2017)
10.1007/s11010-018-3462-1
Role of miRNA-210, miRNA-21 and miRNA-126 as diagnostic biomarkers in colorectal carcinoma: impact of HIF-1α-VEGF signaling pathway
D. Sabry (2018)
10.1038/s41598-018-19458-z
Identification of valid reference genes for mRNA and microRNA normalisation in prostate cancer cell lines
Hui Zhao (2018)
10.1017/erm.2012.6
Molecular pathogenesis of malignant mesothelioma.
P. Rascoe (2012)
10.3390/ncrna5020041
miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery
Jelena Kresoja-Rakic (2019)
10.1186/s13104-019-4113-7
Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case–control study
D. Weber (2019)
10.1371/journal.pone.0018232
Association of MiR-126 with Soluble Mesothelin-Related Peptides, a Marker for Malignant Mesothelioma
L. Santarelli (2011)
10.1016/j.lungcan.2016.05.023
Circulating epigenetic biomarkers in lung malignancies: From early diagnosis to therapy.
M. Tomasetti (2017)
10.1002/gcc.22517
A field guide for cancer diagnostics using cell‐free DNA: From principles to practice and clinical applications
A. Volckmar (2018)
10.1155/2017/9645940
MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study
P. Mozzoni (2017)
10.3390/genes10010032
Epigenetic Biomarkers in Cell-Free DNA and Applications in Liquid Biopsy
W. Gai (2019)
10.1016/j.canlet.2016.05.011
CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.
M. Betti (2016)
10.5858/arpa.2017-0365-RA
Malignant Mesothelioma and Its Non-Asbestos Causes.
R. Attanoos (2018)
Peripheral blood DNA methylation as potential biomarker of malignant Frontiers in Oncology | www.frontiersin.org 8 April 2020 | Volume 10 | Article
S Guarrera (2018)
10.1038/nature03702
MicroRNA expression profiles classify human cancers
J. Lu (2005)
10.1016/j.clinbiochem.2012.02.009
Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients.
M. Tomasetti (2012)
10.1183/09059180.00007014
Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic
O. D. Røe (2015)
10.1371/journal.pone.0030221
Identification of miRNA-103 in the Cellular Fraction of Human Peripheral Blood as a Potential Biomarker for Malignant Mesothelioma – A Pilot Study
D. Weber (2012)
10.1007/s00335-008-9119-8
Cancer-associated genomic regions (CAGRs) and noncoding RNAs: bioinformatics and therapeutic implications
S. Rossi (2008)
10.1101/gr.082701.108
Most mammalian mRNAs are conserved targets of microRNAs.
Robin C Friedman (2009)
10.1016/j.lungcan.2015.09.021
Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma.
L. Santarelli (2015)
10.5271/sjweh.3676
Mesothelioma incidence and asbestos exposure in Italian national priority contaminated sites.
A. Binazzi (2017)
10.1186/s12943-019-0980-8
Extracellular vesicles in the tumor microenvironment: old stories, but new tales
L. Han (2019)
10.5858/arpa.2017-0124-RA
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
A. Husain (2018)
10.1002/ijc.22425
SV40 and human cancer: A review of recent data
K. Shah (2007)
Cancer mortality and incidence of mesothelioma in a cohort of wives of asbestos workers in Casale Monferrato, Italy. Environ Health Perspect
D Ferrante (2007)
Role of miRNA-210, miRNA-21 andmiRNA-126 as diagnostic biomarkers in Frontiers in Oncology | www.frontiersin.org 9 April 2020 | Volume 10 | Article
D Sabry (2019)
10.18632/oncotarget.12408
Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers
I. Bononi (2016)
Diagnostic and prognostic utilities of humoral fibulin-3 inmalignant pleural mesothelioma: evidence from ametaanalysis. Oncotarget
D Pei (2017)
10.1038/nature22364
Phylogenetic ctDNA analysis depicts early stage lung cancer evolution
C. Abbosh (2017)
10.1155/2017/9280170
Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma
D. Weber (2017)
10.1080/09674845.2017.1402404
Potential value of circulating microRNA-126 and microRNA-210 as biomarkers for type 2 diabetes with coronary artery disease
K. Amr (2018)
10.1016/j.jtho.2015.11.005
The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.
F. Galateau-Sallé (2016)
10.3390/ijms17101712
MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions
Caterina Catalanotto (2016)
10.1038/s41598-018-32315-3
Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin – a case-control comparison nested into a prospective cohort of asbestos-exposed workers
G. Johnen (2018)
10.18632/oncotarget.9686
Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis
Luigina Micolucci (2016)
10.1016/j.bbcan.2014.10.001
Liquid biopsies in lung cancer: the new ambrosia of researchers.
C. Rolfo (2014)
10.21037/tlcr.2017.06.06
Targeting the epigenome in malignant pleural mesothelioma.
Kaitlin McLoughlin (2017)
10.1371/journal.pone.0061253
Genetic Variants Associated with Increased Risk of Malignant Pleural Mesothelioma: A Genome-Wide Association Study
G. Matullo (2013)
10.1007/978-1-4939-1804-1_12
Methylation profile landscape in mesothelioma: possible implications in early detection, disease progression, and therapeutic options.
X. Zhang (2015)
Molecular pathogenesis of malignant mesothelioma. Carcinogenesis
Y. Sekido (2013)
10.1007/s00408-016-9868-1
Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure
Melike Demir (2016)
10.1155/2017/3510984
A Novel Panel of Serum Biomarkers for MPM Diagnosis
A. Bonotti (2017)
10.1016/j.reprotox.2016.07.011
Environmental factors, epigenetics, and developmental origin of reproductive disorders.
Shuk-Mei Ho (2017)
10.1016/j.rmr.2017.11.014
[Malignant mesothelioma and constitutional BAP1 gene mutations].
Z. Neviere (2019)
10.1097/JTO.0b013e3182572e83
Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma
M. Kirschner (2012)
10.1073/pnas.1213238109
High prevalence of serum antibodies reacting with simian virus 40 capsid protein mimotopes in patients affected by malignant pleural mesothelioma
E. Mazzoni (2012)
10.1016/j.ctrv.2015.05.001
The established and future biomarkers of malignant pleural mesothelioma.
V. Panou (2015)
10.3109/08958378.2010.497818
The pathological response and fate in the lung and pleura of chrysotile in combination with fine particles compared to amosite asbestos following short-term inhalation exposure: interim results
D. Bernstein (2010)
10.1158/0008-5472.CAN-15-0295
Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.
J. Ohar (2016)
10.5582/bst.2016.01249
Progress of research on microRNAs with diagnostic value in asbestos exposure: A call for method standardization.
Luigina Micolucci (2017)
10.1136/oemed-2014-102297
Malignant mesothelioma due to non-occupational asbestos exposure from the Italian national surveillance system (ReNaM): epidemiology and public health issues
A. Marinaccio (2015)
10.21037/tlcr.2017.05.06
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.
Z. Chen (2017)
10.1038/bjc.2016.151
A circulating miRNA assay as a first-line test for prostate cancer screening
E. Sharova (2016)
10.3389/fgene.2019.00169
Blood Circulating miRNAs as Cancer Biomarkers for Diagnosis and Surgical Treatment Response
Samantha Filipów (2019)
10.1111/j.1349-7006.2012.02223.x
Frequent inactivation of the BAP1 gene in epithelioid‐type malignant mesothelioma
Yoshie Yoshikawa (2012)
10.1002/gcc.22670
Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes
M. Betti (2018)
10.1016/S0169-5002(07)70167-8
Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters.
B. Kroczynska (2006)
10.1016/bs.acc.2018.07.003
Chapter Four Free Circulating miRNAs Measurement in Clinical Settings The Still Unsolved Issue of the Normalization
M. Faraldi (2018)
10.1111/cpr.12589
Tumour biomarkers—Tracing the molecular function and clinical implication
Jiahao Lin (2019)
10.1378/CHEST.122.6.2224
Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area.
S. Metintaş (2002)
10.21037/jtd.2017.10.41
The genetic susceptibility in the development of malignant pleural mesothelioma.
O. Melaiu (2018)
10.1002/ijc.23874
Survival of pleural malignant mesothelioma in Italy: A population‐based study
F. Montanaro (2009)
10.1016/S0092-8674(02)00655-4
A Unified Theory of Gene Expression
G. Orphanides (2002)
10.1002/3527601511.CH1
Five Not Four: History and Significance of the Fifth Base
D. Millar (2005)
10.3402/jev.v4.27066
Biological properties of extracellular vesicles and their physiological functions
M. Yáñez-Mó (2015)
10.1016/j.ctrv.2013.10.003
Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities.
A. Esposito (2014)
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update. Transl Lung Cancer Res
Z Chen (2017)
10.1016/J.LUNGCAN.2006.06.017
Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma.
J. Fischer (2006)
10.1016/j.mrfmmm.2015.08.006
Genetic alterations in periprosthetic soft-tissue masses from patients with metal-on-metal hip replacement.
Virinder Kaur Sarhadi (2015)
10.1016/J.RMR.2017.11.014
Mésothéliomes malins et mutations constitutionnelles du gène BAP1
Z. Neviere (2019)
10.1007/s00408-013-9526-9
Serum Biomarkers in Patients with Mesothelioma and Pleural Plaques and Healthy Subjects Exposed to Naturally Occurring Asbestos
Mehmet Bayram (2013)
10.1373/clinchem.2014.221341
Circulating microRNA biomarker studies: pitfalls and potential solutions.
K. Witwer (2015)
10.5306/wjco.v5.i4.604
MicroRNAs as lung cancer biomarkers.
V. Del Vescovo (2014)
10.3389/fonc.2018.00091
New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma
Marika Rossini (2018)
10.1016/J.MRREV.2019.03.001
Genetic predisposition for malignant mesothelioma: A concise review.
M. Betti (2019)
10.1038/npp.2012.112
DNA Methylation and Its Basic Function
L. Moore (2013)
Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: evidence from a metaanalysis
D Pei (2017)
Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells Frontiers in Oncology | www.frontiersin.org 7 April 2020 | Volume 10 | Article
B Kroczynska (2006)
10.5271/sjweh.3462
Asbestos, asbestosis, and cancer, the Helsinki criteria for diagnosis and attribution 2014: recommendations.
H. Wolff (2015)
10.3390/cancers10040101
Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum
M. L. Thomas (2018)
10.1371/journal.pone.0135331
Two Different Serum MiRNA Signatures Correlate with the Clinical Outcome and Histological Subtype in Pleural Malignant Mesothelioma Patients
M. Lamberti (2015)
10.1016/j.suronc.2014.04.003
A microRNA gene signature for identification of lung cancer.
Z. Xue (2014)
10.1016/j.lungcan.2013.05.014
The role of epigenetics in malignant pleural mesothelioma.
Fabian Vandermeers (2013)
10.1093/carcin/bgt166
Molecular pathogenesis of malignant mesothelioma.
Y. Sekido (2013)
10.21037/jtd.2017.10.126
Exposure to asbestos: past, present and future.
E. Pira (2018)
10.1371/journal.pone.0114483
Combination of MiR-103a-3p and Mesothelin Improves the Biomarker Performance of Malignant Mesothelioma Diagnosis
D. Weber (2014)
10.3233/CBM-2012-00284
MicroRNAs as promising biomarkers for gastric cancer.
F. Wang (2012)
10.1001/jamaoncol.2016.3049
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial
P. Szlosarek (2017)
10.1002/jcb.27586
Clinical significance of serum DRAM1 mRNA, ARSA mRNA, hsa‐miR‐2053 and lncRNA‐RP1‐86D1.3 axis expression in malignant pleural mesothelioma
M. Matboli (2019)
10.1016/S0065-2423(10)52006-7
Methylation of DNA in cancer.
Yoshihisa Watanabe (2010)
10.1093/carcin/bgy167
Circulating microRNAs combined with PSA for accurate and non-invasive prostate cancer detection
M. Mello-Grand (2019)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar